Skip to main
  1. Stocks
  2. Kiniksa Pharmaceuticals Ltd
  3. Forecast
KNSA

KNSA Stock Forecast & Price Target

KNSA Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kiniksa Pharmaceuticals is supported by a durable Arcalyst launch that continues to ramp despite only 23% penetration of the ~14,000 U.S. multiple-recurrence recurrent pericarditis market, leaving substantial room for expansion as prescriber breadth and earlier-line use increase. Its recent quarterly sales growth has averaged about $25MM, FY26 revenue guidance was raised to $1.045-$1.050B, and strong operating results show positive annual cash flow, with 3Q26 operating income of $54.2MM, net income of $47.3MM, and $568.8MM in cash and investments. The upside case is further strengthened by KPL-387, a wholly owned, once-monthly program with H2:2027 data expected that could improve adherence, support a gradual switch from Arcalyst, and lift EPS through better economics and additional pipeline optionality.

Bears say

Kiniksa Pharmaceuticals is vulnerable to slower-than-expected commercial adoption of Arcalyst in recurrent pericarditis, which undermines confidence in its ability to convert a clinical-stage portfolio into durable revenue growth. The outlook is further weakened by the risk that competing therapies could prove better than expected, limiting market share and reducing the long-term value of its programs. In addition, if biologics for rare diseases fail to secure premium pricing at commercialization, the company’s economics could disappoint, especially given its heavy reliance on the United States for revenue.

KNSA has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kiniksa Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

KNSA Analyst Forecast & Price Prediction

Get the latest KNSA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KNSA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kiniksa Pharmaceuticals Ltd (KNSA) Forecast

Analysts have given KNSA a Strong Buy based on their latest research and market trends.

According to 8 analysts, KNSA has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kiniksa Pharmaceuticals Ltd (KNSA)


KNSA Analyst Forecast & Price Prediction

Get the latest KNSA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KNSA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KNSA stock data and trends